Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Articles

Catalent has signed an agreement with Therachon to support preclinical and clinical development of TA-46, a novel protein being developed to treat achondroplasia.

Catalent Biologics Collaborates with Therachon to Develop Novel Protein Therapy for Achondroplasia

Catalent has been working together with Lexicon to develop the drug formulation of Xermelo, which has now been approved by FDA for the treatment of carcinoid syndrome diarrhea.

Catalent to Manufacture Lexicon Pharmaceuticals' Orphan Drug Xermelo

James P. Agalloco is the president of Agalloco & Associates, P.O. Box 899, Belle Mead, NJ 08502, tel. 908.874.7558, jagalloco@aol.com. He is also a member of Pharmaceutical Technology’s editorial advisory board.

Understanding the purpose of the biological indicator can guide the development of an effective sterilization process.

Kill the Bioburden, Not the Biological Indicator

Catherine Shaffer is a contributing writer to BioPharm International, cathshaffer@gmail.com.

A multi-pronged approach to raw materials testing can help mitigate the risk of future contamination events.

Ensuring the Biological Integrity of Raw Materials

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

The decision to use disposable bioreactors is now driven by commercial rather than technological considerations.

Single-Use Bioreactors Have Reached the Big Time

Manufacturing for originator molecules is restricted by regulations, but drug makers can exploit newer technologies for the manufacture of biosimilars.

Cost Considerations Drive Lean Technology in Biomanufacturing

Bosch’s Xelum platform is designed for continuous production of oral solid-dosage forms.

Bosch Introduces Continuous OSD Manufacturing Platform

The program aims to make biosimilars for the treatment of cancer more widely available in middle- and low-income countries.


WHO Launches Biosimilar Pilot Program

EMA and the European Commission released a biosimilars information guide for health professionals during the EC’s biosimilars conference.


EMA Promotes Understanding and Use of Biosimilars

Forecasts were lowered, Reuters reported, due to reduced drug approvals and increased competitive pressures.